FDA Approves Taxol as Adjuvant Therapy for Node+ Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

ROCKVILLE, Md-The Food and Drug Administration has approved a new indication for Bristol-Myers Squibb’s Taxol (paclitaxel) for use in the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-based combination therapy. The approval does not exclude patients with receptor-positive tumors, even though a subgroup analysis of the supporting data suggested no benefit in this group.

ROCKVILLE, Md—The Food and Drug Administration has approved a new indication for Bristol-Myers Squibb’s Taxol (paclitaxel) for use in the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-based combination therapy. The approval does not exclude patients with receptor-positive tumors, even though a subgroup analysis of the supporting data suggested no benefit in this group.

The approval came only a month after a unanimous recommendation for approval by the FDA’s Oncologic Drugs Advisory Committee (ODAC). (See Oncology News International, October 1999, page 4, for a full report of the meeting.)

At the ODAC meeting, Bristol-Myers Squibb presented data on more than 3,000 patients in a randomized phase III study. The results showed that the adjuvant use of Taxol reduced the risk of breast cancer recurrence in node-positive patients by 22% and reduced mortality by 28%, compared with patients who received doxorubicin-based chemotherapy alone.

The indication states: “In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone negative tumors.”

The agent was first approved in the United States in late 1992 for the second-line treatment of ovarian cancer. It has since won approval for use in breast cancer after failure of combination chemotherapy for metastatic disease; for the first-line treatment of ovarian cancer in combination with cisplatin (Platinol); for the second-line treatment of AIDS-related Kaposi’s sarcoma; and in combination with cisplatin for the first-line treatment of non-small-cell lung cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content